These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 34342419)

  • 21. Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis.
    Durgam S; Earley W; Lu K; Németh G; Laszlovszky I; Volk S; Litman RE
    Int J Clin Pract; 2017 Dec; 71(12):. PubMed ID: 29119668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial.
    Durgam S; Starace A; Li D; Migliore R; Ruth A; Németh G; Laszlovszky I
    Bipolar Disord; 2015 Feb; 17(1):63-75. PubMed ID: 25056368
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cariprazine: A Review in Schizophrenia.
    Garnock-Jones KP
    CNS Drugs; 2017 Jun; 31(6):513-525. PubMed ID: 28560619
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
    Kiss B; Horváth A; Némethy Z; Schmidt E; Laszlovszky I; Bugovics G; Fazekas K; Hornok K; Orosz S; Gyertyán I; Agai-Csongor E; Domány G; Tihanyi K; Adham N; Szombathelyi Z
    J Pharmacol Exp Ther; 2010 Apr; 333(1):328-40. PubMed ID: 20093397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The dopamine D₃-preferring D₂/D₃ dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia.
    Watson DJG; King MV; Gyertyán I; Kiss B; Adham N; Fone KCF
    Eur Neuropsychopharmacol; 2016 Feb; 26(2):208-224. PubMed ID: 26723167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mini Review on Cariprazine: A Promising Antipsychotic Agent.
    Patel A; Patel A; Patel D; Patel K; Bambharoliya T
    CNS Neurol Disord Drug Targets; 2023; 22(2):226-236. PubMed ID: 35331126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology.
    Neill JC; Grayson B; Kiss B; Gyertyán I; Ferguson P; Adham N
    Eur Neuropsychopharmacol; 2016 Jan; 26(1):3-14. PubMed ID: 26655189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The novel atypical antipsychotic cariprazine demonstrates dopamine D
    Delcourte S; Ashby CR; Rovera R; Kiss B; Adham N; Farkas B; Haddjeri N
    CNS Neurosci Ther; 2018 Dec; 24(12):1129-1139. PubMed ID: 29729086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cariprazine, a new type - dopamine D₃ receptor preferring - partial agonist atypical antipsychotic for the treatment of schizophrenia and the primary negative symptoms].
    Laszlovszky I; Kiss B; Barabassy A; Kapas M; Nemeth G
    Neuropsychopharmacol Hung; 2019 Sep; 21(3):103-118. PubMed ID: 31537751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The preclinical discovery and development of cariprazine for the treatment of schizophrenia.
    Wesołowska A; Partyka A; Jastrzębska-Więsek M; Kołaczkowski M
    Expert Opin Drug Discov; 2018 Aug; 13(8):779-790. PubMed ID: 29722587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cariprazine in Bipolar Depression and Mania: State of the Art.
    Mazza M; Marano G; Traversi G; Carocci V; Romano B; Janiri L
    CNS Neurol Disord Drug Targets; 2018; 17(10):723-727. PubMed ID: 30152291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics, Safety, and Tolerability of Cariprazine in Pediatric Patients with Bipolar I Disorder or Schizophrenia.
    Riccobene T; Riesenberg R; Yeung PP; Earley WR; Hankinson AL
    J Child Adolesc Psychopharmacol; 2022 Oct; 32(8):434-443. PubMed ID: 36282772
    [No Abstract]   [Full Text] [Related]  

  • 33. [Pharmacology of antipsychotics at human dopamine D2 and D3 receptors].
    Tadori Y; Kikuchi T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Feb; 32(1):9-18. PubMed ID: 22568121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study.
    Earley W; Burgess MV; Rekeda L; Dickinson R; Szatmári B; Németh G; McIntyre RS; Sachs GS; Yatham LN
    Am J Psychiatry; 2019 Jun; 176(6):439-448. PubMed ID: 30845817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine.
    Choi YK; Adham N; Kiss B; Gyertyán I; Tarazi FI
    CNS Spectr; 2017 Dec; 22(6):484-494. PubMed ID: 28059046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor-Dependent Antidepressant Effects in the Chronic Stress Model.
    Duric V; Banasr M; Franklin T; Lepack A; Adham N; Kiss B; Gyertyán I; Duman RS
    Int J Neuropsychopharmacol; 2017 Oct; 20(10):788-796. PubMed ID: 28531264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dopamine D2 and D4 receptor ligands: relation to antipsychotic action.
    Wilson JM; Sanyal S; Van Tol HH
    Eur J Pharmacol; 1998 Jun; 351(3):273-86. PubMed ID: 9721018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical potential of cariprazine in the treatment of acute mania.
    Altınbaş K; Guloksuz S; Oral ET
    Psychiatr Danub; 2013 Sep; 25(3):207-13. PubMed ID: 24048386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The dopamin D3 receptor--the gray eminence of pharmacotherapy?].
    Sumegi A; Varga E
    Neuropsychopharmacol Hung; 2010 Sep; 12(3):405-11. PubMed ID: 20962360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of cariprazine in the treatment of bipolar disorder.
    Saraf G; Pinto JV; Yatham LN
    Expert Opin Pharmacother; 2019 Dec; 20(17):2063-2072. PubMed ID: 31644326
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.